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Botulinum toxin type A reduces  
histamine-induced itch and  
vasomotor responses in human skin
This study was designed to investigate the effect of subcutane-
ous administration of botulinum toxin type A (BTX) on experi-
mentally histamine-induced itch in human skin. In this double-
blind, placebo-controlled study, BTX reduced the histamine-
induced itch intensity (F1,39 = 30.2, P < 0.001) and itch area 
(F1,39 = 8.8, P = 0.011) compared with saline at all time points 
after treatment. The duration of itch was also shorter for BTX-
treated areas (F1,39 = 19.4, P < 0.001), with a peak effect at day 
7. The flare area was smaller in the BTX-treated arm compared 
with the saline-treated arm at all time points after treatment 
(F1,39 = 15.4, P = 0.002). Findings from blood flow (F1,26 = 177.3, 
P < 0.001) and temperature measurements (F1,26 = 27.6, P < 
0.001) clearly showed the suppressive effect of BTX on vaso-
motor reactions, with the maximal effect on days 3 and 7. BTX 
reduced the itch intensity, blood flow and neurogenic inflam-
mation in response to the histamine prick test in human skin. Br 
J Dermatol 2009; 161: 737–45.
Botulinum toxin abolishes sweating  
via impaired sweat gland responsiveness  
to exogenous acetylcholine
The aim of this study was to test the hypothesis that botulinum 
toxin A (BTX) is capable of altering sweating by reducing the 
responsiveness of the sweat gland to incremental doses of ace-
tylcholine. A relative absence of sweating was observed at sites 
injected with BTX (mean ± SD 0.05 ± 0.09 and 0.03 ± 0.04 mg 
cm−2 min−1, both at the highest dose of acetylcholine, for two 
different test protocols), while sweat rate increased appropri-
ately at the control sites (0.90 ± 0.46 and 1.07 ± 0.67 mg cm−2 
min−1, respectively). Cutaneous vascular conductance increased 
to a similar level at both the BTX and control sites. These results 
demonstrate that BTX is capable of inhibiting sweat secretion 
by reducing the responsiveness of the sweat gland to acetyl-
choline, while not altering acetylcholine-mediated cutaneous 
vasodilatation. Br J Dermatol 2009; 161: 757–61.
Filaggrin mutations may confer susceptibility 
to chronic hand eczema characterized by 
combined allergic and irritant contact dermatitis
The aim of this investigation was to evaluate the role of muta-
tions in the FLG gene in the development of chronic hand 
eczema (CHE). In total, 122 German patients with clearly 
defined CHE subtypes were screened for the FLG variants 
R501X and 2282del4 by polymerase chain reaction and 
restriction enzyme digest analysis. The prevalence of these 
variants in patients with CHE was compared with that in 95 
healthy individuals. Overall allele frequency and the number 
of mutation carriers were similar in both the CHE and control 
groups. When classified according to clearly defined CHE 
subtypes, however, the nonfunctional FLG variants showed an 
association with CHE involving an aetiological combination 
of contact allergy and irritant factors [P = 0.04; P (exact test) 
= 0.06; P (difference in rates) = 0.09; 95% confidence interval 
(CI) 0–56.8], or with excessive daily exposure to water and 
irritants [P = 0.003; P (difference in rates) < 0.001; 95% CI 
29.3–67.9]. Br J Dermatol 2009; 161: 801–7.
Cellular and molecular features of lipoma tissue: 
comparison with normal adipose tissue
This study analysed cellular and transcriptional characteristics of 
lipoma tissue compared with normal adipose tissue, further to 
delineate differentiating features. Immunohistochemistry indi-
cated enhanced adipogenesis in lipoma compared with normal 
adipose tissue. In contrast, cellular apoptosis was not enhanced 
in lipoma, suggesting that the enlargement of lipoma tissue 
may be due to a positive balance of adipocyte turnover (accel-
erated adipogenesis combined with nonenhanced apoptosis). 
Leptin mRNA was upregulated in lipoma, while adiponectin, 
tumour necrosis factor-α and glucose transporter 1 mRNA 
were downregulated and there were no apparent changes in 
hypoxia-inducible factor 1α, peroxisome proliferator-activated 
receptor-γ and plasminogen activator inhibitor-1. These results 
suggested dysfunction of lipoma adipocytes similar to that in 
obesity, but indicated that lipoma tissue lacked several obesity-
related phenomena such as ischaemia (hypoxia), macrophage 
infiltration, inflammatory reactions and enhanced glycolysis. 
Adipose-derived stem/progenitor/stromal cells from lipoma and 
normal adipose tissue showed similar proliferative and adipo-
genic capacity. Br J Dermatol 2009; 161: 819–25.
Incidence of bullous pemphigoid  
and pemphigus in Switzerland:  
a 2-year prospective study
The aims of this study were: (i) to evaluate the incidence 
of bullous pemphigoid (BP) and pemphigus vulgaris (PV)/
pemphigus foliaceus (PF) in Swiss patients; and (ii) to assess 
the profile of the patients, particularly for comorbidities and 
medications. All newly diagnosed cases of BP and pemphi-
gus occurring between 1 January 2001 and 31 December 
2002 were collected. In total, 168 patients with these auto-
immune bullous diseases, with a diagnosis based on clinical, 
histological and immunopathological criteria, were includ-
ed. BP showed a mean incidence of 12.1 new cases per mil-
lion people per year. Its incidence increased significantly 
after the age of 70 years. The age-standardized incidence of 
BP using the European population as reference was, how-
ever, lower, with 6.8 new cases per million people per year, 
reflecting the ageing of the Swiss population. In contrast, 
both PV and PF were less frequent. Their combined mean 
annual incidence was 0.6 new cases per million people per 
year. Br J Dermatol 2009; 161: 861–8.
